Holds one active US DMF and one valid CEP for carmustine, filing since 2016. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 26 markets.
Holds one active US DMF and one valid CEP for carmustine, filing since 1998. Its 2025 FDA inspection closed as NAI, and its GMP is recognised in 1 market.
Holds one active US DMF and one valid CEP for carmustine, filing since 2018. Its GMP is recognised in 2 markets.
Holds one active US DMF for carmustine, filing since 2017. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 8 markets.
Holds 2 active US DMFs for carmustine, filing since 2020. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 15 markets.
Holds one active US DMF and one valid CEP for carmustine, filing since 2017. Its 2025 FDA inspection closed as VAI.
Holds one active US DMF for carmustine, filing since 2009. Its 2024 FDA inspection closed as VAI.
Registered with SFDA (Saudi Arabia) for carmustine. Its 2023 FDA inspection closed as VAI, and its GMP is recognised in 3 markets.
Holds one active US DMF for carmustine, filing since 2017.
Holds one active US DMF for carmustine, filing since 1993.
Holds one active US DMF for carmustine, filing since 2023.
The names are listed below. The filings, inspection history and GMP certificates behind each one are available with a free account.
Contract manufacturers make to order rather than holding their own filing for this molecule.
The order is set by active filings weighted by regulator, inspection outcomes and their recency, breadth of GMP recognition, and evidence of real exports, less any open risk flags. Every factor appears on the card it produced. Read the full method.
Tell us which markets you need to file in. These suppliers come back tiered for those markets, with the price corridor and an RFI sheet.
Start for free